Core Viewpoint - The stock of Innovent Biologics (01801) rose nearly 3% towards the end of trading, with a current increase of 2.62% at HKD 92, and a trading volume of HKD 747 million [1] Group 1: Clinical Research and Drug Development - On November 20, Innovent Biologics announced that its drug IBI362 (Mastuzumab injection) achieved its primary endpoint and all key secondary endpoints in a Phase III clinical study (GLORY-2) conducted in the Chinese population with moderate to severe obesity [1] - The company plans to submit a new drug application for Mastuzumab 9mg for adult weight management to regulatory authorities in the near future [1] Group 2: Drug Profile and Collaboration - Mastuzumab is a dual receptor agonist for glucagon (GCG) and glucagon-like peptide-1 (GLP-1), co-developed by Innovent Biologics and Eli Lilly, and is the first GCG/GLP-1 dual receptor agonist approved globally [1] - The drug has already received approval in China for two indications: long-term weight management in adults with obesity or overweight, and blood glucose control in adults with type 2 diabetes [1]
信达生物尾盘涨近3% 公司将递交玛仕度肽9mg用于成人体重控制的新药上市申请